Last 12 months
Inside the activity.
0 purchase rows · 14 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 6 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2020 Filed Sep 3, 2020 16:12 UTC |
Bhavnagri VeerGeneral Counsel
|
SaleCommon Stock | 400 | $35.89 | $14,356.00 |
DisclosureSEC source: 0001214659-20-007671 · marketforms-49584.xml · nonDerivative · entry 3 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,902 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2020. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:12 UTC |
Bhavnagri VeerGeneral Counsel
|
SaleCommon Stock | 24,600 | $35.35 | $869,610.00 |
DisclosureSEC source: 0001214659-20-007671 · marketforms-49584.xml · nonDerivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,302 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.87 to $35.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:12 UTC |
Bhavnagri VeerGeneral Counsel
|
Exercise / conversionCommon Stock | 25,000 | $2.27 | $56,750.00 |
DisclosureSEC source: 0001214659-20-007671 · marketforms-49584.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2020 Filed Apr 2, 2021 20:11 UTC Amendment |
Chang David DDirector · President and CEO
|
GiftCommon Stock | 205,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-003892 · marketforms-52165.xml · nonDerivative · entry 4 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 856,044 F4 · kind: On August 31, 2020, Robert Chang transferred 205,778 shares of the Issuer's common stock to the RTC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's son is the beneficiary. F5 · ownership.nature: Securities held in the name of the RTC 2019 Trust dated October 1, 2019. Read SEC document |
| August 31, 2020 Filed Apr 2, 2021 20:11 UTC Amendment |
Chang David DDirector · President and CEO
|
GiftCommon Stock | 205,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-003892 · marketforms-52165.xml · nonDerivative · entry 3 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 856,044 F2 · kind: On August 31, 2020, Julia Chang transferred 205,778 shares of the Issuer's common stock to the JEC 2019 Trust dated October 1, 2019, of which the Reporting Person and Jane Chang are Trustees and the Reporting Person's daughter is the beneficiary. F3 · ownership.nature: Securities held in the name of the JEC 2019 Trust dated October 1, 2019. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:04 UTC |
MOORE ALISONChief Technical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 32,451 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001214659-20-007184 · marketforms-49454.xml · derivative · entry 2 MOORE ALISON · CIK 0001754937 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 685,751 Underlying: Common Stock · 32,451 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:04 UTC |
MOORE ALISONChief Technical Officer
|
Exercise / conversionCommon Stock | 32,451 | $2.27 | $73,663.77 |
DisclosureSEC source: 0001214659-20-007184 · marketforms-49454.xml · nonDerivative · entry 1 MOORE ALISON · CIK 0001754937 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 16:34 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 7,686 | $37.70 | $289,730.69 |
DisclosureSEC source: 0001387131-20-007268 · ownership.xml · nonDerivative · entry 5 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 18,716,306 F2 · shares: The Distribution and the sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the TPG Funds and the TPG Sales Vehicles, respectively. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.51 to $37.99, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F7 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. F8 · ownership.nature: TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 12,477,536 shares of Common Stock. The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P., which directly holds 6,238,770 shares of Common Stock. F9 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F10 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 16:34 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 5,605 | $37.02 | $207,505.51 |
DisclosureSEC source: 0001387131-20-007268 · ownership.xml · nonDerivative · entry 4 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 18,723,992 F2 · shares: The Distribution and the sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the TPG Funds and the TPG Sales Vehicles, respectively. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $37.47, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F7 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. F8 · ownership.nature: TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 12,477,536 shares of Common Stock. The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P., which directly holds 6,238,770 shares of Common Stock. F9 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F10 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 16:34 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 19,554 | $37.33 | $730,001.66 |
DisclosureSEC source: 0001387131-20-007268 · ownership.xml · nonDerivative · entry 3 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 18,729,597 F2 · shares: The Distribution and the sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the TPG Funds and the TPG Sales Vehicles, respectively. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.90 to $37.76, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F7 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. F8 · ownership.nature: TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 12,477,536 shares of Common Stock. The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P., which directly holds 6,238,770 shares of Common Stock. F9 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F10 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 16:34 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 4,600 | $38.22 | $175,792.68 |
DisclosureSEC source: 0001387131-20-007268 · ownership.xml · nonDerivative · entry 2 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 18,749,151 F2 · shares: The Distribution and the sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the TPG Funds and the TPG Sales Vehicles, respectively. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.92 to $38.53, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F7 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. F8 · ownership.nature: TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 12,477,536 shares of Common Stock. The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P., which directly holds 6,238,770 shares of Common Stock. F9 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F10 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 16:34 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
OtherCommon Stock | 962,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-20-007268 · ownership.xml · nonDerivative · entry 1 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 18,753,751 F1 · kind: Effective August 6, 2020, TPG Carthage Holdings, L.P. and The Rise Fund Carthage, L.P. (collectively, the "TPG Funds") distributed, in accordance with their limited partnership agreements, an aggregate of 1,000,000 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. (the "Issuer") to their limited partners, some of which made further pro rata distributions of the shares of Common Stock to their limited partners (the "Distribution"), with some of the foregoing that are affiliated with TPG Group Holdings (SBS) Advisors, Inc. having established 10b5-1 trading plans for the sale of the shares of Common Stock received in the Distribution (those whose sales are reported in this Form 4, the "TPG Sales Vehicles"). F2 · shares: The Distribution and the sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the TPG Funds and the TPG Sales Vehicles, respectively. F1 · price: Effective August 6, 2020, TPG Carthage Holdings, L.P. and The Rise Fund Carthage, L.P. (collectively, the "TPG Funds") distributed, in accordance with their limited partnership agreements, an aggregate of 1,000,000 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. (the "Issuer") to their limited partners, some of which made further pro rata distributions of the shares of Common Stock to their limited partners (the "Distribution"), with some of the foregoing that are affiliated with TPG Group Holdings (SBS) Advisors, Inc. having established 10b5-1 trading plans for the sale of the shares of Common Stock received in the Distribution (those whose sales are reported in this Form 4, the "TPG Sales Vehicles"). F7 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. F8 · ownership.nature: TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 12,477,536 shares of Common Stock. The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P., which directly holds 6,238,770 shares of Common Stock. F9 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F10 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:09 UTC |
Bhavnagri VeerGeneral Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001214659-20-006805 · marketforms-49403.xml · derivative · entry 4 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,800 Underlying: Common Stock · 25,000 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:09 UTC |
Bhavnagri VeerGeneral Counsel
|
SaleCommon Stock | 16,450 | $37.29 | $613,397.47 |
DisclosureSEC source: 0001214659-20-006805 · marketforms-49403.xml · nonDerivative · entry 3 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,902 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.95 to $37.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:09 UTC |
Bhavnagri VeerGeneral Counsel
|
SaleCommon Stock | 15,103 | $36.46 | $550,723.34 |
DisclosureSEC source: 0001214659-20-006805 · marketforms-49403.xml · nonDerivative · entry 2 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,352 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.95 to $36.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:09 UTC |
Bhavnagri VeerGeneral Counsel
|
Exercise / conversionCommon Stock | 25,000 | $2.27 | $56,750.00 |
DisclosureSEC source: 0001214659-20-006805 · marketforms-49403.xml · nonDerivative · entry 1 Bhavnagri Veer · CIK 0001808980 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2020 Filed Jun 30, 2020 16:53 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 59,747 | $42.21 | $2,522,052.31 |
DisclosureSEC source: 0001387131-20-006093 · ownership.xml · nonDerivative · entry 3 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 19,716,306 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.60, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,144,202 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,572,104 shares of Common Stock. F5 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F6 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 29, 2020 Filed Jun 30, 2020 16:53 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 24,904 | $43.27 | $1,077,543.78 |
DisclosureSEC source: 0001387131-20-006093 · ownership.xml · nonDerivative · entry 2 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 19,776,053 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.60 to $43.595, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,144,202 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,572,104 shares of Common Stock. F5 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F6 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 16:53 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 500 | $44.01 | $22,005.00 |
DisclosureSEC source: 0001387131-20-006093 · ownership.xml · nonDerivative · entry 1 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 19,800,957 F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,144,202 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,572,104 shares of Common Stock. F5 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F6 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 25, 2020 Filed Jun 25, 2020 18:24 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 72,359 | $44.19 | $3,197,327.13 |
DisclosureSEC source: 0001387131-20-005972 · tpg-form4_062320.xml · nonDerivative · entry 4 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 19,801,457 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.01 to $44.445, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,200,970 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,600,487 shares of Common Stock. F7 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 18:24 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 15,269 | $43.93 | $670,713.73 |
DisclosureSEC source: 0001387131-20-005972 · tpg-form4_062320.xml · nonDerivative · entry 3 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 19,873,816 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.91 to $43.98, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,200,970 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,600,487 shares of Common Stock. F7 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 18:24 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 22,213 | $44.31 | $984,235.82 |
DisclosureSEC source: 0001387131-20-005972 · tpg-form4_062320.xml · nonDerivative · entry 2 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 19,889,085 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.18 to $44.53, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,200,970 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,600,487 shares of Common Stock. F7 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 18:24 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 110,012 | $43.91 | $4,830,373.89 |
DisclosureSEC source: 0001387131-20-005972 · tpg-form4_062320.xml · nonDerivative · entry 1 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 19,911,298 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.18 to $44.1775, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,200,970 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,600,487 shares of Common Stock. F7 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 22, 2020 Filed Jun 22, 2020 18:25 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 42,855 | $43.16 | $1,849,827.50 |
DisclosureSEC source: 0001387131-20-005873 · ownership.xml · nonDerivative · entry 4 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 20,021,310 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.01 to $43.32, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,347,538 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,673,772 shares of Common Stock. F7 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 22, 2020 Filed Jun 22, 2020 18:25 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 129,570 | $42.72 | $5,534,893.52 |
DisclosureSEC source: 0001387131-20-005873 · ownership.xml · nonDerivative · entry 3 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 20,064,165 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.01 to $43.005, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,347,538 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,673,772 shares of Common Stock. F7 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 18:25 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 47,767 | $42.04 | $2,008,306.19 |
DisclosureSEC source: 0001387131-20-005873 · ownership.xml · nonDerivative · entry 2 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 20,193,735 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.01 to $42.155, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,347,538 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,673,772 shares of Common Stock. F7 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 18:25 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 94,600 | $42.14 | $3,986,595.36 |
DisclosureSEC source: 0001387131-20-005873 · ownership.xml · nonDerivative · entry 1 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 20,241,502 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.05 to $42.265, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,347,538 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,673,772 shares of Common Stock. F7 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 17, 2020 Filed Jun 17, 2020 18:13 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 87,319 | $42.18 | $3,683,482.16 |
DisclosureSEC source: 0001387131-20-005745 · ownership.xml · nonDerivative · entry 3 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 20,336,102 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.01 to $42.53, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,557,398 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,778,704 shares of Common Stock. F6 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F7 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 18:13 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 174,511 | $42.20 | $7,364,678.32 |
DisclosureSEC source: 0001387131-20-005745 · ownership.xml · nonDerivative · entry 2 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 20,423,421 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.01 to $42.835, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,557,398 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,778,704 shares of Common Stock. F6 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F7 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 18:13 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 129,154 | $42.14 | $5,442,885.36 |
DisclosureSEC source: 0001387131-20-005745 · ownership.xml · nonDerivative · entry 1 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 20,597,932 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.01 to $42.42, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,557,398 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,778,704 shares of Common Stock. F6 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F7 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:04 UTC |
Kazam Joshua ADirector
|
GrantCommon Stock | 9,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-005494 · marketforms-49012.xml · nonDerivative · entry 1 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,305 Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:05 UTC |
Humer Franz BDirector
|
GrantCommon Stock | 9,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-005495 · marketforms-49011.xml · nonDerivative · entry 1 Humer Franz B · CIK 0001548072 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,216 Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:06 UTC |
WITTE OWEN N.Director
|
GrantCommon Stock | 9,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-005496 · marketforms-49010.xml · nonDerivative · entry 1 WITTE OWEN N. · CIK 0001700969 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,151 Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:03 UTC |
MESSEMER DEBORAH M.Director
|
GrantStock Option (Right to Buy) · Derivative | 16,640 | $0.00 Strike: $42.63 | $0.00 |
DisclosureSEC source: 0001214659-20-005493 · marketforms-49013.xml · derivative · entry 1 MESSEMER DEBORAH M. · CIK 0001754424 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,640 Underlying: Common Stock · 16,640 shares Expires 2030-06-05 F1 · derivative.exercise_date: The stock option vests in 12 equal monthly installments beginning July 5, 2020. Read SEC document |
| June 04, 2020 Filed Jun 4, 2020 20:04 UTC |
Belldegrun ArieDirector
|
PurchaseCommon Stock | 106,382 | $47.00 | $4,999,954.00 |
DisclosureSEC source: 0001214659-20-005383 · marketforms-48964.xml · nonDerivative · entry 2 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,798,163 F2 · ownership.nature: The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| June 04, 2020 Filed Jun 4, 2020 20:04 UTC |
Belldegrun ArieDirector
|
PurchaseCommon Stock | 40,000 | $47.00 | $1,880,000.00 |
DisclosureSEC source: 0001214659-20-005383 · marketforms-48964.xml · nonDerivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 40,000 F1 · ownership.nature: The securities are held in the name of Bellco Legacy LLC (Bellco Legacy). Bellco Legacy is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 17:43 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 1,818 | $47.11 | $85,638.16 |
DisclosureSEC source: 0001387131-20-005509 · allo-form4_060320.xml · nonDerivative · entry 3 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 20,727,086 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.06 to $47.185, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,818,055 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,909,031 shares of Common Stock. F6 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F7 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 17:43 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 274,080 | $47.13 | $12,916,814.83 |
DisclosureSEC source: 0001387131-20-005509 · allo-form4_060320.xml · nonDerivative · entry 2 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 20,728,904 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.50 to $47.47, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,818,055 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,909,031 shares of Common Stock. F6 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F7 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 17:43 UTC |
BONDERMAN DAVIDDirector · 10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 213,322 | $47.75 | $10,185,698.86 |
DisclosureSEC source: 0001387131-20-005509 · allo-form4_060320.xml · nonDerivative · entry 1 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · Director · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 21,002,984 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.50 to $48.02, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of each of (i) TPG GenPar VII Advisors, LLC and (ii) The Rise Fund GenPar Advisors, LLC. TPG GenPar VII Advisors, LLC is the general partner of TPG GenPar VII, L.P., which is the general partner of TPG Carthage Holdings, L.P., which directly holds 13,818,055 shares of Common Stock ("Common Stock") of Allogene Therapeutics, Inc. F2 · ownership.nature: The Rise Fund GenPar Advisors, LLC is the general partner of The Rise Fund GenPar, L.P., which is the general partner of The Rise Fund Carthage, L.P. (together with TPG Carthage Holdings, L.P., the "TPG Funds"), which directly holds 6,909,031 shares of Common Stock. F6 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each TPG Fund and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any. F7 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:33 UTC |
Kazam Joshua ADirector
|
OtherCommon Stock | 8,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-003820 · marketforms-48642.xml · nonDerivative · entry 1 Kazam Joshua A · CIK 0001221355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,023,336 F1 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:32 UTC |
Chang David DDirector · President and CEO
|
OtherCommon Stock | 9,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-003819 · marketforms-48643.xml · nonDerivative · entry 2 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,224,101 F3 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:32 UTC |
Chang David DDirector · President and CEO
|
OtherCommon Stock | 9,198 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-003819 · marketforms-48643.xml · nonDerivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,201,108 F1 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019. F2 · ownership.nature: Securities held in the name of the Chang 2006 Family Trust. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:37 UTC |
Amado RafaelEVP of R&D and CMO
|
GrantStock Option (Right to Buy) · Derivative | 109,600 | $0.00 Strike: $18.22 | $0.00 |
DisclosureSEC source: 0001214659-20-002804 · marketforms-48393.xml · derivative · entry 2 Amado Rafael · CIK 0001662119 · EVP of R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,600 Underlying: Common Stock · 109,600 shares Expires 2030-03-17 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:37 UTC |
Amado RafaelEVP of R&D and CMO
|
GrantCommon Stock | 30,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-002804 · marketforms-48393.xml · nonDerivative · entry 1 Amado Rafael · CIK 0001662119 · EVP of R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,962 Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:38 UTC |
Belldegrun ArieDirector
|
GrantStock Option (Right to Buy) · Derivative | 379,066 | $0.00 Strike: $18.22 | $0.00 |
DisclosureSEC source: 0001214659-20-002807 · marketforms-48389.xml · derivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,066 Underlying: Common Stock · 379,066 shares Expires 2030-03-17 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:37 UTC |
Chang David DDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 568,600 | $0.00 Strike: $18.22 | $0.00 |
DisclosureSEC source: 0001214659-20-002806 · marketforms-48390.xml · derivative · entry 1 Chang David D · CIK 0001611024 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,600 Underlying: Common Stock · 568,600 shares Expires 2030-03-17 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:37 UTC |
MOORE ALISONChief Technical Officer
|
GrantStock Option (Right to Buy) · Derivative | 109,600 | $0.00 Strike: $18.22 | $0.00 |
DisclosureSEC source: 0001214659-20-002805 · marketforms-48391.xml · derivative · entry 2 MOORE ALISON · CIK 0001754937 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,600 Underlying: Common Stock · 109,600 shares Expires 2030-03-17 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:37 UTC |
MOORE ALISONChief Technical Officer
|
GrantCommon Stock | 30,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-002805 · marketforms-48391.xml · nonDerivative · entry 1 MOORE ALISON · CIK 0001754937 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,821 Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:36 UTC |
SCHMIDT ERIC THOMASChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 109,600 | $0.00 Strike: $18.22 | $0.00 |
DisclosureSEC source: 0001214659-20-002803 · marketforms-48392.xml · derivative · entry 3 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,600 Underlying: Common Stock · 109,600 shares Expires 2030-03-17 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:36 UTC |
SCHMIDT ERIC THOMASChief Financial Officer
|
GrantCommon Stock | 30,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-002803 · marketforms-48392.xml · nonDerivative · entry 1 SCHMIDT ERIC THOMAS · CIK 0001754403 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,706 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.